Follow Prelude Therapeutics Incorporated to never miss an important update.
The FDA cleared the company to begin human testing for PRT13722, an oral drug designed to treat a specific type of breast cancer. This drug is a selective KAT6A degrader, which works by breaking down a protein that helps cancer cells grow while aiming to avoid the side effects of older, less precise treatments.
This is a critical step for the company as it moves from the lab into clinical trials. If the early data shows the drug is safe and effective, it could validate the company's approach to targeted cancer therapy and potentially attract larger pharmaceutical partners.
Source: GlobeNewsWire
Management has a perfect record of beating their own loss estimates for two years. They consistently set a low bar, suggesting the business is more efficient with its cash than they let on.
| Expectation | |
|---|---|
| EPS | $-0.16 |
| Revenue | $28M |
Follow Prelude Therapeutics Incorporated to get the latest and most important updates.
Follow PRLD